Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Basal Cell 14Neoplasms 5Skin Neoplasms 4Pancreatic Neoplasms 4Basal Cell Nevus Syndrome 4Prostatic Neoplasms 3Breast Neoplasms 3Neoplasm Metastasis 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Carcinoma 2Adenocarcinoma 2Thrombocytosis 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-Resistant Fallopian Tube Carcinoma 1Pancreatic Diseases 1Ovarian Neoplasms 1Odontogenic Cysts 1Neuroectodermal Tumors, Primitive 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

atezolizumab 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Platinum-Resistant Fallopian Tube Carcinoma × HhAntag691 × Clear all
NCT05538091 2025-11-26

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

University of Pittsburgh

Phase 2 Recruiting
48 enrolled
Gynecologic

Platinum-Resistant Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡